详情页 - 河北大学附属医院知识库

当前位置：首页 > 详情页

Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

9| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd. [2]Peking Union Medical College Hospital,Beijing,Beijing,China,100730 [3]The First Affiliated Hospital of Sun Yat sen University,Guangzhou,Guangdong,China,510062 [4]Zhujiang Hospital of Southern Medical University,Guangzhou,Guangdong,China,510260 [5]Qingyuan Hospital Affiliated to Guangzhou Medical University,Qingyuan,Guangdong,China,511518 [6]The First Affiliated Hospital of Shantou University Medical College,Shantou,Guangdong,China,515041 [7]Liuzhou General Hospital,Liuzhou,Guangxi,China,545026 [8]The Affiliated Hospital of Hebei University,Baoding,Hebei,China,050031 [9]The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China,150007 [10]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Henan,China,233099 [11]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China,450052 [12]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052 [13]Union Hospital, Tongji Medical College of huazhong university of science and technology,Wuhan,Hubei,China,430022 [14]Xiangya Hospital Central South University,Changsha,Hunan,China,140008 [15]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029 [16]The Second Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shaanxi,China,710004 [17]The First Hospital of Shanxi Medical University,Taiyuan,Shanxi,China,030001 [18]West China Hospital of Sichuan University,Chengdu,Sichuan,China,610044 [19]Sichuan Provincial People''s Hospital,Chengdu,Sichuan,China,610072 [20]The First Affiliated Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China,830054

研究目的：

A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.